A new study found that fair prices for medications like Wegovy and Zepbound would be hundreds less per month than they are ...

To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...

"People come together, operators, with their supervisors at 6 a.m. every morning, and they talk about what issues they have and how they propose to solve it. Those get escalated through all levels of ...

When you or your bed partner has sleep apnea, a restful night’s sleep can be hard to come by. Treating this common condition ...

It's not too often that pharmaceutical drugs become household names, but that's happening with medicines in the weight loss ...

Novo Nordisk A/S shares plunged the most since December after another disappointment for the drugmaker’s next-generation shot ...

Demand for Wegovy and Zepbound is booming, but supply issues and limited insurance coverage have curtailed access to the pricey medications.

Eli Lilly and Company’s LLY shares dipped almost 5% on Monday after rival Novo Nordisk NVO announced disappointing data from ...

Presiding over the upward trajectory of Eli Lilly over the last eight years is paying off nicely for CEO David Ricks. | ...

Novo’s share price fell 8 per cent on Monday, having previously dived in December after a late-stage trial of CagriSema in ...

Eli Lilly CEO Dave Ricks made $114 million last year, according to a new proxy statement, a rare instance of a health ...

Novo Nordisk’s share price plunged the most since December after another disappointment for the drugmaker’s next-generation ...